Articles related to OVER-THE-COUNTER (OTC) REMEDIES

The FDA classified a recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief as a Class II event after the manufacturer identified sterility concerns and potential contamination affecting a single lot.

The FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding a device previously limited to adults and supporting caregiver-supervised home glucose monitoring.

The FDA has approved an OTC switch for adapalene/benzoyl peroxide gel (Differin Epiduo) for patients 12 and older, expanding adolescent access to a fixed-dose retinoid combination without a prescription or clinical visit.

Hemarthrosis affects an estimated 70–80% of people with hemophilia and can progress to permanent joint damage, with pain management presenting a specific medication safety intersection point for pharmacists at the OTC counter and bedside.

A nationwide recall of more than 3 million OTC eye drops due to sterility concerns highlights the importance of routine patient counseling around non‑prescription ocular products.

Pharmacists are instrumental in recognizing MOH, counseling patients who rely on analgesics more than twice weekly, and encouraging preventive therapies.